Recap: Amicus Therapeutics Q2 Earnings

Shares of Amicus Therapeutics FOLD rose 0.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).

Revenue of $62,353,000 rose by 41.29% from the same period last year, which missed the estimate of $62,380,000.

Outlook

The upcoming fiscal year's revenue expected to be between $250,000,000 and $260,000,000.

Conference Call Details

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/fvhk9nzf

Price Action

Company's 52-week high was at $16.13

Company's 52-week low was at $6.25

Price action over last quarter: Up 32.05%

Company Profile

Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!